Introduction
Substantial differences exist in the serum 25(OH)D response observed among individuals following vitamin D supplementation [1] [2] [3] . It is logical that such differences are due, at least in part, to between-individual variation in vitamin D absorption, degradation, and distribution. However, vitamin D absorption has not been widely studied, as assays for cholecalciferol have historically been challenging [4] . Nonetheless, existing, albeit limited, data do document substantial between-individual variation in vitamin D absorption [5] [6] [7] [8] , which could contribute to variability in 25(OH)D observed following supplementation. Additionally, some reports suggest that enhanced 24-hydroxylation, the first step in vitamin D degradation, predicts a less robust 25(OH)D increase after supplementation [9, 10] . Thus, poorer absorption, manifesting as a less robust cholecalciferol increase, and/or greater degradation, manifesting as a higher 24,25(OH) 2 D or 24, 25(OH) 2 D/25(OH)D ratio, might result in a less robust 25(OH)D increase following supplementation in a given individual. As such, knowledge of these vitamin D metabolite levels may allow personalization of the vitamin D dose needed to achieve a target 25(OH)D level. Fortunately, advances in liquid chromatography tandem mass spectroscopy (LC-MS/ MS) methodology, recognized as the gold standard for 25(OH)D measurement [11] , have recently made cholecalciferol and 24,25(OH) 2 D measurements available [12] [13] [14] [15] .
Despite the known variability of 25(OH)D response to supplementation, virtually all expert recommendations endorse, and most randomized prospective studies have utilized, a single fixed vitamin D dose for all individuals, an approach that does not assure attainment of any pre-defined, "target" 25(OH)D level. Such fixed dose approaches, and subsequent meta-analytic evaluation of dose administered, have served to fuel the controversy surrounding how to define vitamin D inadequacy, since some people experience little or no serum 25(OH)D increase following what many would consider highdose vitamin D supplementation. Individuals with no, or minimal, change in 25(OH)D would be expected to have no physiologic effect; however, such subjects are included in the "supplemented" group for meta-analysis. Therefore, it is not surprising that meta-analyses that have focused on dose administered, rather than response obtained, have failed to clearly define vitamin D inadequacy. [16] Understanding the causes of variation in 25(OH)D level attained following supplementation, and consideration of this variable response in future clinical trials, will allow a biologically meaningful definition of vitamin D inadequacy to be established. To this end, the purpose of this study was to explore the utility of cholecalciferol and 24,25(OH) 2 D measurements to predict serum 25(OH)D level attained following vitamin D supplementation.
Methods

Subjects
Data from 91 postmenopausal women whose baseline 25(OH)D was between 10.0-29.9 ng/mL and who received either 2300 or 2500 IU of vitamin D 3 daily in one of two placebo-controlled oral vitamin D supplementation trials were combined for use in this study. The serum 25(OH)D range was selected as various expert groups consider such individuals to have suboptimal vitamin D status. Inclusion criteria for these two studies were virtually identical; subjects were generally healthy community-dwelling women without known conditions contraindicating vitamin D supplementation or interfering with vitamin D absorption. The duration of vitamin D supplementation was either 4 or 6 months. The time of study supplement dosing was not specified; all serum specimens were obtained in the morning from 0800 to 1100. Supplement compliance was assessed by returned pill count. Vitamin D 3 study preparation content was independently validated to contain the stated cholecalciferol amount. Baseline serum cholecalciferol and 25(OH)D did not differ between these two cohorts. The University of Wisconsin Health Sciences Institutional Review Board approved both studies. Statistical analysis/prediction model development Study cohort differences were evaluated by factorial ANOVA; vitamin D metabolite relationships at baseline and at 4-6 months were evaluated using multiple regression following data transformation as necessary to satisfy parametric assumptions. All analyses were performed using SigmaStat (San Jose, CA).
Results
Vitamin D metabolite concentrations
Study participants were 62.3±8.9 (mean ± SD) years of age with a BMI of 29. 2 D in these 91 women at baseline and study end is depicted in Fig. 1 . Notably, serum cholecalciferol was unmeasurable in 64/91 of these women at baseline but only 11/91 at study end.
While the mean 25(OH)D increased by ∼14 ng/mL, on an individual basis, the 25(OH)D change observed following daily vitamin D 3 supplementation varied dramatically, from −11 to +45 ng/mL, as noted in Fig. 2 . Indeed, 24 women (26 %) in this group did not achieve a 25(OH)D level above 30 ng/mL and the final value for 6 was below 20 ng/mL. In contrast, nine attained a 25(OH)D value >50 ng/mL. An obvious potential cause of a low 25(OH)D increase is poor supplement compliance; however, this does not appear to explain the observed variability. 
Discussion
Vitamin D supplementation trials generally use fixed doses and fail to consider between-individual variability of the 25(OH)D response [1, 2, 17] . In this report, we demonstrate that a substantial amount of the between-individual variation in 25(OH)D observed following supplementation can be attributed to differences in absorption and degradation as assessed by serum cholecalciferol and 24,25(OH) 2 D, respectively. While it is widely accepted that vitamin D supplementation produces a greater 25(OH)D increase in those whose baseline level is lower [18] , this is not always true. Indeed, two people with identical 25(OH)D levels can experience markedly different 25(OH)D increments following supplementation (examples denoted by rectangles in Fig. 2 ). In these examples, the baseline cholecalciferol level for subjects a and b were both not detectable (i.e., <0.1 ng/mL) whereas at follow up, the cholecalciferol concentration of subject a increased to 4.6 ng/ mL, but subject b remained undetectable despite 99 % compliance with supplementation. Additionally, subjects c and d started with virtually identical 25(OH)D levels, but subject c declined, perhaps due to this individual having one of the highest 24,25(OH) 2 D/25(OH)D ratios at follow up. Importantly, her supplementation compliance was 92 %. Given such variable response, using a "one-size-fits-all" dose will not assure attaining a 25(OH)D level above any arbitrary cutpoint, e.g., 30 ng/mL, unless the selected dose is very large. However, conducting clinical trials using huge doses would be unwise, as some people attain 25(OH)D values of ∼60 ng/ mL with a dose as low as 2500 IU (e.g., cross in Fig. 2 ), levels associated with increases in cancer risk and overall mortality [19, 20] . Rather than using single fixed doses, or alternatively, using huge doses to assure a 25(OH)D value above a given target level, in this report, we demonstrate that measuring cholecalciferol and 24,25(OH) 2 D can account for approximately half the observed inter-individual variation in response to vitamin D supplementation. Having the capability to individually tailor vitamin D supplementation dose using readily obtainable, patient-specific data will allow improved study design for future vitamin D trials. It is reasonable to expect that the model developed here can subsequently be improved based upon additional clinical trials. Assuming this to be the case, it is reasonable to assume that a model can be developed to facilitate attaining a target level of 25(OH)D in clinical practice, i.e., a "treat-to-target" dosing strategy, while simultaneously avoiding supplementation to potentially toxic levels. Future work to define such an approach is indicated.
There are important limitations to this study, which must be acknowledged. First, it is based on a relatively small number of subjects, all of whom were postmenopausal women. Thus, the generalizability of these results to other populations is unknown. Second, the full regression model requires vitamin D measurement both prior to and following supplementation; an ideal model would include only baseline vitamin D metabolite measurements. Perhaps larger studies and/or improvements in cholecalciferol measurement capabilities that allow detection of lower serum values will permit inclusion of baseline cholecalciferol level into the prediction equation thereby addressing this limitation. Additionally, further study is needed to determine how cholecalciferol dose contributes to the change in 25(OH)D levels. Importantly, the ability to predict 25(OH)D response to vitamin D supplementation does not address the much more fundamental question of what the ideal serum 25(OH)D concentration should be. It seems unlikely that this question will be answered if prospective trials do not address the variation in 25(OH)D response highlighted in this study. Finally, the current model does not include all potential contributors to 25(OH)D status, e.g., season. Indeed, i n t h i s s t u d y, t h e m e a n 2 5 ( O H ) D i n c r e a s e postsupplementation was numerically highest when the follow-up blood draw occurred in summer or fall. However, emphasizing the importance of dose individualization, three of the five women who experienced a 25(OH)D decline had their follow-up level obtained in the fall, at which one could have expected their 25(OH)D to have been highest resulting from summer sun. In addition to season, other potential confounders including skin pigmentation, amount/time of sun exposure, and amount of skin exposed were not considered in this work, as how to clinically apply such information in a given patient is unclear; nevertheless, such limitations do confound the ability to predict 25(OH)D response to supplementation. Finally, the time of vitamin D supplement dosing was not specified; clearly defining time of supplement dosing and subsequent blood collection may further improve utility of serum cholecalciferol measurement.
These limitations notwithstanding, our data unequivocally demonstrate that there is a wide individual variation in the 25(OH)D response to daily vitamin D 3 supplementation. A single reasonable fixed dose (e.g., 2500 IU daily) of supplemental vitamin D will leave many below a widely accepted 25(OH)D target (30 ng/mL) and even some below the more conservative target of 20 ng/mL, while raising others to a level that may have potential long-term toxicity. Thus, fixed dose studies will not clearly define what constitutes vitamin D inadequacy. In contrast, individualizing supplementation to achieve a biological target, e.g., a pre-specified 25(OH)D level, could accomplish this goal. Our empirically derived regression model leads to a proposed improvement in supplementation strategy, akin to those commonly used in titrating anticoagulants, and is amenable to explicit testing and modification/improvement in future trials. Moreover, by conceptualizing the observed relationship of 25(OH)D and its metabolites as a consequence of differences in surrogates for vitamin D absorption and clearance, we have established a framework for investigating individual variation in vitamin D turnover.
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